Mark Fesler
4 weeks
Valuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
Trying to stomach multiple myeloma: A case report - PubMed
We report a case of a 51-year-old male with minimal past medical history who presented to his primary care provider with nausea, vomiting and constipation in the outpatient setting. Concomitantly, ..... see more
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma - PubMed
Chimeric antigen receptor (CAR) T cells are highly successful in the treatment of hematologic malignancies. We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with ..... see more
Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development - PubMed
Although light-chain amyloidosis (AL) and multiple myeloma (MM) are characterized by tumor plasma cell (PC) expansion in bone marrow (BM), their clinical presentation differs. Previous attempts to identify unique pathogenic ..... see more
SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma - PubMed
doi: 10.1186/s40364-021-00296-7. 1 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2 Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. 3 Department of ..... see more
Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure? - PubMed
Nowadays, several novel agents have been introduced in the treatment of multiple myeloma, not only resulting in high response rates and prolonged survival but also offering good quality of life. ..... see more
Multiple Myeloma: From Baby Steps to Giant Strides
The past three decades have witnessed major paradigm shifts in the management of multiple myeloma (MM), resulting in significant improvements not only in the survival from the diagnosis but also ..... see more
Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift
Multiple myeloma (MM) is a genetically heterogenous disease and remains mostly incurable with a small group of patients achieving long-term disease remission. The past decade witnessed enormous efforts to break ..... see more
Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions - PubMed
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. ..... see more
Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP Inhibitor in multiple myeloma - PubMed
Multiple myeloma (MM) is a malignancy of antibody-producing plasma cells with genomic instability and genetic abnormality as its two hallmarks. Therefore, DNA damage is pervasive in MM cells, which indicates ..... see more
Population Pharmacokinetics of Belantamab Mafodotin, a BCMA-targeting Agent in Patients with Relapsed/Refractory Multiple Myeloma - PubMed
Belantamab mafodotin (belamaf) is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). Nonlinear mixed-effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), ..... see more
Review of Venetoclax in CLL, AML and Multiple Myeloma - PubMed
Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be explored, ..... see more
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells - PubMed
The lysine demethylase KDM2A (also known as JHDM1A or FBXL11) demethylates histone H3 at lysine K36 which lead to epigenetic regulation of cell proliferation and tumorigenesis. However, many biological processes ..... see more
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial - PubMed
doi: 10.1186/s12885-021-08325-2. 1 Department of Haematology and Oncology, Würzburg University Medical Center, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. knop_s@ukw.de. 2 University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, ..... see more
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma - PubMed
doi: 10.1007/s00432-021-03668-6. Online ahead of print. 1 Department of Hematology, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto, Tokushima, 770-8539, Japan. ozaki@tph.gr.jp. 2 Department of Hematology, Gunma University Graduate School of Medicine, ..... see more
M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (β5i) delivering efficacy in multiple myeloma models - PubMed
2021 May 27;molcanther.MCT-21-0005-A.2021. doi: 10.1158/1535-7163.MCT-21-0005. Online ahead of print. 1 Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany michael.sanderson@merckgroup.com. 2 Merck KGaA. 3 Merck KGaA, Darmstadt, Germany. 4 ..... see more
Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma - PubMed
doi: 10.3389/fphar.2021.651523. 1 Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 2 Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 3 Fundação Ezequiel Dias, ..... see more
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma - PubMed
Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial ..... see more
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Bortezomib- and lenalidomide-based therapies have become standard front-line treatment for multiple myeloma (MM),1 resulting in many patients being refractory to bortezomib or lenalidomide at first relapse.2, 3 This may negatively ..... see more
Source : https://onlinelibrary.wiley.com/doi/10.1111/bjh.17541
Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma - PubMed
Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States. Treatment for eligible patients involves induction, consolidation with stem cell ..... see more
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received ..... see more
Show More Comments
-
-
Multiple Myeloma Connect 4 weeks
Please share your thoughts concerning overdose on oral chemotherapy.